CL2023001201A1 - Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados - Google Patents

Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados

Info

Publication number
CL2023001201A1
CL2023001201A1 CL2023001201A CL2023001201A CL2023001201A1 CL 2023001201 A1 CL2023001201 A1 CL 2023001201A1 CL 2023001201 A CL2023001201 A CL 2023001201A CL 2023001201 A CL2023001201 A CL 2023001201A CL 2023001201 A1 CL2023001201 A1 CL 2023001201A1
Authority
CL
Chile
Prior art keywords
treatment
hair loss
deuterated
regimens
loss disorders
Prior art date
Application number
CL2023001201A
Other languages
English (en)
Spanish (es)
Inventor
Cassella James
Original Assignee
Sun Pharmaceuticals Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceuticals Ind Inc filed Critical Sun Pharmaceuticals Ind Inc
Publication of CL2023001201A1 publication Critical patent/CL2023001201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023001201A 2020-10-28 2023-04-26 Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados CL2023001201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US202163155637P 2021-03-02 2021-03-02

Publications (1)

Publication Number Publication Date
CL2023001201A1 true CL2023001201A1 (es) 2023-11-17

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001201A CL2023001201A1 (es) 2020-10-28 2023-04-26 Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados

Country Status (14)

Country Link
US (1) US20230390292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023553253A (cg-RX-API-DMAC7.html)
KR (1) KR20230093504A (cg-RX-API-DMAC7.html)
AU (1) AU2021372512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001201A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006808A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000085A (cg-RX-API-DMAC7.html)
IL (1) IL302401A (cg-RX-API-DMAC7.html)
JO (1) JOP20230090A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005027A (cg-RX-API-DMAC7.html)
PE (1) PE20231945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022094133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215520A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
MX2023005027A (es) 2023-07-31
AU2021372512A1 (en) 2023-06-22
JP2023553253A (ja) 2023-12-21
US20230390292A1 (en) 2023-12-07
PE20231945A1 (es) 2023-12-05
EP4236956A1 (en) 2023-09-06
CO2023006808A2 (es) 2023-09-08
CA3196551A1 (en) 2022-05-05
IL302401A (en) 2023-06-01
DOP2023000085A (es) 2023-07-31
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
JOP20230090A1 (ar) 2023-04-27
KR20230093504A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
CO2023006808A2 (es) Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados
MX2018013347A (es) Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2021001951A1 (es) Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los desordenes asociados a la edad.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CR20240308A (es) Inhibidores de parp7
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
PE20241326A1 (es) Composiciones y tratamientos con nirogacestat
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2025007935A (es) Nuevos inhibidores reversibles de dpp1 y usos de estos
CL2022001102A1 (es) Métodos para el tratamiento de trastornos depresivos.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
DOP2025000167A (es) Inhibidores de prmt5–mta
MX2024013641A (es) Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
AR131842A1 (es) Métodos para tratar gliomas
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
AR128870A1 (es) Inhibidores de tyk2 y usos de los mismos
MX2025014596A (es) Metodos para tratar la dermatomiositis con brepocitinib
AR132852A1 (es) Combiterapia para tratar el cáncer
MX2023011686A (es) Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos.
WO2025189114A8 (en) Cdk inhibitors and their use as pharmaceuticals
AR121415A1 (es) INHIBIDORES DE LA QUINASA p38 QUE REDUCEN LA EXPRESIÓN DE DUX4 Y DE LOS GENES CORRIENTE ABAJO PARA USO EN EL TRATAMIENTO DE FSHD